Home > Boards > US Listed > Biotechs > Neon Therapeutics (NTGN)

Neon Therapeutics News: NTGN Stock Rockets 38% on

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Rsarabjit Member Profile
 
Followed By 71
Posts 10,219
Boards Moderated 0
Alias Born 02/01/16
160x600 placeholder
Termination of Registration of a Class of Security Under Section 12(b) (15-12b) Edgar (US Regulatory) - 5/18/2020 6:09:23 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/6/2020 5:10:57 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 5/6/2020 5:04:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2020 4:47:18 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 5/6/2020 10:48:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2020 5:11:22 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/1/2020 8:39:04 AM
Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01 GlobeNewswire Inc. - 4/30/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2020 5:33:24 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 4/29/2020 5:31:48 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/21/2020 4:31:49 PM
WeissLaw LLP Investigates Neon Therapeutics, Inc. PR Newswire (US) - 4/10/2020 7:45:00 PM
Proxy Statement - Merger or Acquistion (definitive) (defm14a) Edgar (US Regulatory) - 4/2/2020 5:00:12 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/2/2020 9:01:53 AM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 3/31/2020 5:10:59 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 3/31/2020 4:06:38 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 3/31/2020 7:56:45 AM
BioNTech Announces Full Year 2019 Financial Results and Corporate Update GlobeNewswire Inc. - 3/31/2020 6:42:46 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/27/2020 2:29:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/25/2020 5:29:39 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/23/2020 8:17:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/2/2020 6:40:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/2/2020 6:40:09 PM
Rsarabjit   Thursday, 01/16/20 04:52:17 PM
Re: None
Post # of 14 
Neon Therapeutics News: NTGN Stock Rockets 38% on BioNTech Deal

BioNTech is acquiring Neon Therapeutics

By William White, InvestorPlace Writer Jan 16, 2020, 4:06 pm EST

Neon Therapeutics (NASDAQ:NTGN) news for Thursday about a deal with BioNTech (NASDAQ:BNTX) has NTGN stock soaring on Thursday.

?

Source: Shutterstock.com

A Neon Therapeutics news releasereveals that BioNTech is going to be acquiring the company. This will have it purchasing all shares of NTGN stock in a deal valued at roughly $67.00 million.
The deal will have Neon Therapeutics merging with Endor Lights, which is a wholly-owned subsidiary of BioNTech. Investors in NTGN stock will receive 0.063 shares of BNTX stock in exchange for each NTGN share that they own.
This offer for NTGN stock values it at $2.18 per share. That’s based on BNTX stock’s closing price of $34.55 on Wednesday. The offer of $2.18 per share for NTGN stock is a roughly 77.24% premium over its closing price of $1.23 on Wednesday.
Ugur Sahin, MD, co-founder and CEO of BioNTech, says this about the deal with Neon Therapeutics.

“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline. I am particularly excited about the adoptive T cell and neoantigen TCR therapies being developed by Neon, which are complementary to our pipeline and our focus on solid tumors.”

The Neon Therapeutics news release notes that the deal has the full support of the company’s Board of Directors. Approval from shareholders and regulators is still needed. So long as there are no problems here, the deal will close in the second quarter of 2020.
NTGN stock was up 38.21% and BNTX stock was down 6.66% when markets closed on Thursday.



https://investorplace.com/2020/01/neon-therapeutics-news-ntgn-stock-rockets-38-on-biontech-deal/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences